Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Blood (2025) 146 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2025-3399

Published: 2025

Journal Articles

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Nitin Jain, Fadi Haddad, Partow Kebriaei, Issa Khouri, Elizabeth Shpall, Richard Champlin, Jayastu Senapati, Eitan Kugler, Omer Karrar, Elias Maroun, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian, Nicholas Short

Blood (2025) 146 (Supplement 1): 549.

https://doi.org/10.1182/blood-2025-549

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL

Eitan Kugler, Ken Furudate, Farhad Ravandi, Nitin Jain, Gautam Borthakur, Nicholas Short, Rebecca Garris, Hagop Kantarjian, Elias Jabbour, Koichi Takahashi

Blood (2025) 146 (Supplement 1): 5151.

https://doi.org/10.1182/blood-2025-5151

Published: 2025

Journal Articles

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Blood (2025) 146 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2025-4294

Published: 2025

Journal Articles

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

Eitan Kugler, Jayastu Senapati, Sanam Loghavi, Farhad Ravandi, Alexandre Bazinet, Alex Bataller, Courtney DiNardo, Danielle Hammond, Kelly Chien, Wei-Ying Jen, Guillermo Montalban-Bravo, Koji Sasaki, Gautam Borthakur, Hagop Kantarjian, Guillermo Garcia-Manero, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2025-3206

Published: 2025

Journal Articles

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Jayastu Senapati, Elias Jabbour, Nitin Jain, Kelly Chien, Musa Yilmaz, Fadi Haddad, Guillermo Montalban-Bravo, Eitan Kugler, Wei-Ying Jen, Rita Khouri, Maro Ohanian, Rebecca Garris, Min Zhao, Guillermo Garcia-Manero, Nicholas Short, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 1573.

https://doi.org/10.1182/blood-2025-1573

Published: 2025

Journal Articles

Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring

Trevor Jamison, Elias Jabbour, Nitin Jain, Omer Karrar, Fadi Haddad, Partow Kebriaei, Issa Khouri, Uday Popat, Hui Yang, Jayastu Senapati, Eitan Kugler, Rebecca Garris, Guillermo Garcia-Manero, Hagop Kantarjian, Nicholas Short

Blood (2025) 146 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2025-1558

Published: 2025

Journal Articles

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Roberta S. Azevedo, Hagop Kantarjian, Jayastu Senapati, Ian Bouligny, Alexandre Bazinet, Wei-Ying Jen, Amin Alousi, Uday Popat, Elizabeth Shpall, Naveen Pemmaraju, Nitin Jain, Eitan Kugler, Cody Belgarde, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2025-1630

Published: 2025

Journal Articles

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2025-6075

Published: 2025

Journal Articles

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Jennifer Marvin-Peek, Hagop M. Kantarjian, Wei-Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti, Nicholas J. Short, Steven M. Kornblau, Naveen Pemmaraju, Eitan Kugler, Alexandre Bazinet, Yesid Alvarado-Valero, Hussein A. Abbas, Guillermo Garcia-Manero, Uday Popat, Elizabeth J. Shpall, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2024-202414

Published: 2024

Journal Articles

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Jennifer Marvin-Peek, Courtney D. DiNardo, Wei-Ying Jen, Nicholas J. Short, Yesid Alvarado Valero, Gautam Borthakur, Naval Daver, Eitan Kugler, Alexandre Bazinet, Hussein A. Abbas, Musa Yilmaz, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2024-202405

Published: 2024

Journal Articles

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

Nicholas J. Short, Hagop Kantarjian, Nitin Jain, Koichi Takahashi, Ken Furudate, Jayastu Senapati, Fadi G. Haddad, Omer Karrar, Tapan M. Kadia, Kelly S. Chien, Koji Sasaki, Eitan Kugler, Rebecca Garris, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 837.

https://doi.org/10.1182/blood-2024-206602

Published: 2024

Journal Articles

A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Nitin Jain, Jayastu Senapati, Fadi G. Haddad, Omer Karrar, Kelly S. Chien, Eitan Kugler, Adaeze Elechi, Regina Abramova, Min Zhao, Rebecca Garris, Marina Konopleva, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2024-206487

Published: 2024

Journal Articles

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Eitan Kugler, Hagop M. Kantarjian, Alexandre Bazinet, Wei-Ying Jen, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Jayastu Senapati, Gautam Borthakur, Naveen Pemmaraju, Ghayas C. Issa, Alex Bataller, Patrick K. Reville, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2861.

https://doi.org/10.1182/blood-2024-199903

Published: 2024

Journal Articles

Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis

Eitan Kugler, Sanam Loghavi, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Ghayas C. Issa, Hussein A. Abbas, Prithviraj Bose, Jayastu Senapati, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 2857.

https://doi.org/10.1182/blood-2024-199917

Published: 2024

Journal Articles

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Walid Macaron, Elias Jabbour, Nitin Jain, Fadi G. Haddad, Jayastu Senapati, Partow Kebriaei, Eitan Kugler, Kelly S. Chien, Ghayas C. Issa, Jairo Matthews, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 727.

https://doi.org/10.1182/blood-2024-203929

Published: 2024

Journal Articles

Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant

Eitan Kugler, Niranjan Shiwaji Khaire, Elias Jabbour, Nicholas J. Short, Tapan M. Kadia, Fadi G. Haddad, Koji Sasaki, Rashmi Kanagal-Shamanna, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian, Nitin Jain

Blood (2024) 144 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2024-211903

Published: 2024

Journal Articles

Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics

Anna Gurevich Shapiro, Eitan Winter, Yakir Moshe, Yonatan Katzenelenbogen, Diego Jaitin, Mor Zada, Oren Barboy, Ido Yofe, Paulina Chalan, San Truong Phan, Amir Giladi, Michael Shapiro, Renana Robinson, Eitan Kugler, Ofir Wolach, Irit Avivi Mazza, Ido Amit

Blood (2023) 142 (Supplement 1): 599.

https://doi.org/10.1182/blood-2023-188930

Published: 2023

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.

Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant

Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only